Adopting a Fully Digital Launch Model in the Future for Biopharma

CHAPEL HILL, N.C., Jan. 18, 2021/PRNewswire/ -- Many companies delayed drug launches, paused new clinical trials, and reduced workforces as a result of the global pandemic, making traditional field-based launches impossible.

However, after reviewing business, social and market factors, Biohaven pivoted to a full digital launch model and boldly entered the market.

Best Practices, LLC produced a case study “Pure Play Digital Launch: Launching a New Blockbuster Migraine Drug During a Global Pandemic” which examines Nurtec's trailblazing, pure play digital launch that found a path to success despite the challenges of the COVID-19 pandemic.

This assessment probes how Biohaven embraced new technology, digital education, and digital messaging approaches to support one of the industry's first and most successful all-digital launches - which may prove an important milestone and roadmap for many other biopharma manufacturers in the future.

To learn more about this report, download a complimentary report excerpt at https://www.best-in-class.com/rw94.htm.

ABOUT BEST PRACTICES, LLC

Best Practices, LLC is a leading benchmarking, consulting and advisory services firm serving biopharmaceutical and medical device companies worldwide. Best Practices, LLC's clients include all the top 10 and 48 of the top 50 global healthcare companies. The firm conducts primary research and consulting using its comprehensive proprietary benchmarking tools and analysis. The operational insights, findings and analysis form the basis for our Benchmarking Reports, databases and advisory services to support executives in commercial and R&D operations.

Disclaimer: Biohaven is not affiliated with Best Practices, LLC and Biohaven has not sponsored, endorsed or supported this analysis.